Physician

Anita Rajasekhar, MD

According to 2025 Medicare claims, Anita Rajasekhar, MD (NPI: 1437247822) practices hematology in the Gainesville, FL market, with the plurality of this provider's patient population coming from Alachua, FL. This provider's primary affiliated billing organization is FLORIDA CLINICAL PRACTICE ASSOCIATION INC (NPI: 1063463768; TIN: 59-1680273) and primary practice location at 32610-3008. Rajasekhar is affiliated with the UF HEALTH ACO GAINESVILLE, LLC (ACO ID: A5468) and American Choice Healthcare, LLC (ACO ID: D0086), participating under both the MSSP and REACH models.

Rajasekhar's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 243 traditional Medicare patients, billed 481 HCPCS/CPT codes, and received $33,560 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 238 prescription claims across 42 beneficiaries totaling $35,459 in drug costs, led by Eliquis (Apixaban). Open Payments data shows 9 records totaling $30,142. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $21,598 and ending at $35,459. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	194	420	$36,544
2016	217	518	$43,509
2017	265	518	$41,998
2018	297	524	$41,137
2019	280	518	$42,290
2020	266	485	$40,171
2021	238	371	$33,423
2022	200	336	$31,042
2023	189	297	$27,312
2024	243	481	$33,560

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	35	101	$21,598
2016	33	103	$44,593
2017	39	128	$19,666
2018	34	138	$42,742
2019	37	136	$27,164
2020	32	154	$156,268
2021	41	170	$33,372
2022	48	238	$50,137
2023	25	157	$22,660
2024	42	238	$35,459

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	25	25	$125
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	36	37	$102
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	111	128	$90
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	27	43	$60
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	118	140	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	19	844	$16,738
Oxycontin	Oxycodone Hcl	12	337	$9,530
Morphine Sulfate Er	Morphine Sulfate	70	2,130	$2,442
Oxycodone Hcl	Oxycodone Hcl	62	1,532	$1,173
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	19	455	$453

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$53	Genentech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	8	$30,088	Takeda Pharmaceuticals U.S.A., Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Anita Rajasekhar, MD?

Tedicare shows public-source Medicare data for Anita Rajasekhar, MD (NPI 1437247822), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Anita Rajasekhar, MD have ACO affiliation data?

Anita Rajasekhar, MD is shown with ACO affiliation data for UF HEALTH ACO GAINESVILLE, LLC (MSSP, ACO ID A5468) and American Choice Healthcare, LLC (REACH, ACO ID D0086).

What billing organization is linked to Anita Rajasekhar, MD?

Anita Rajasekhar, MD is linked to FLORIDA CLINICAL PRACTICE ASSOCIATION INC (billing NPI 1063463768) in the available physician profile data.

Does Anita Rajasekhar, MD have Open Payments data?

Anita Rajasekhar, MD has 9 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.